The immune checkpoint inhibitor avelumab showed promising antitumor activity and a manageable toxicity profile in patients with platinum-refractory metastatic urothelial carcinoma, according to a new analysis.
The PARP inhibitor talazoparib significantly increased progression-free survival over physician’s choice of therapy in a randomized phase III trial of patients with advanced breast cancer and a germline BRCA mutation.
Treatment with anamorelin significantly increased lean body mass and improved anorexia symptoms in patients with advanced non–small-cell lung cancer, according to a new study conducted in Japan.
A study found that circulating tumor cells are predictive of late recurrence in patients with hormone receptor–positive, HER2-negative early breast cancer.
Adding vistusertib to fulvestrant failed to demonstrate a benefit over everolimus in patients with ER-positive advanced or metastatic breast cancer.
An antibody–drug conjugate known as sacituzumab govitecan demonstrated significant clinical activity in heavily pretreated patients with relapsed/refractory metastatic triple-negative breast cancer, according to a new study.
A study found no difference in outcomes between 2 and 5 years of treatment with zoledronate after chemotherapy in early breast cancer patients, suggesting the longer duration may not be necessary.
The combination of pembrolizumab and trastuzumab showed promising clinical benefit in patients with trastuzumab-resistant HER2-positive advanced breast cancer who express PD-L1, according to a new study.
The addition of the CDK4/6 inhibitor ribociclib to endocrine therapy with either tamoxifen or an aromatase inhibitor significantly improved progression-free survival among premenopausal and perimenopausal women with breast cancer.
Increasing chemotherapy dose intensity reduced the risk of recurrence and death over standard chemotherapy regimens, according to a meta-analysis of women with early-stage breast cancer.